GlassScriptPhysician profile
Jason Douglas Blanchard
NPI 1457747271
$9,590.07
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,884 · 2021: $1,498 · 2022: $1,451 · 2023: $966 · 2024: $2,791.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,029 · Food and Beverage: $717 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,028.92 |
| Food and Beverage | $716.73 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Treace Medical Concepts, INC. | $4,527.69 | 2021-2024 | |
| Elite Orthopedics, LLC | $3,855.36 | 2019-2024 | |
| Abbvie INC. | $227.37 | 2022-2024 | Dalvance, Teflaro |
| Amgen INC. | $117.25 | 2019 | |
| Nevro Corp. | $99.26 | 2022-2023 | Senza |
| Novo Nordisk INC | $66.47 | 2022-2024 | Wegovy, Rybelsus |
| Paratek Pharmaceuticals, INC. | $65.67 | 2024 | Nuzyra |
| Radius Health, INC. | $58.70 | 2023-2024 | Tymlos |
| Merck Sharp & Dohme LLC | $57.97 | 2019-2023 | Zerbaxa, Recarbrio, Dificid |
| Organogenesis INC. | $57.50 | 2022-2023 | Puraply |
| Kerecis Limited | $54.61 | 2023-2024 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Janssen Pharmaceuticals, INC | $52.69 | 2019 | |
| Alexion Pharmaceuticals, INC. | $49.64 | 2023 | |
| Celularity INC. | $42.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $29.45 | 2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $23.36 | 2024 | Mounjaro |
| Bioventus LLC | $23.07 | 2019 | |
| Ascensia Diabetes Care US INC. | $21.51 | 2022 | |
| Dexcom, INC. | $21.02 | 2021 | |
| Chiesi USA, INC. | $19.92 | 2024 | Mycapssa |
| Averitas Pharma INC. | $19.64 | 2023 | Qutenza |
| Melinta Therapeutics, LLC | $18.88 | 2022 | |
| Halozyme INC | $17.55 | 2023 | |
| Kyowa Kirin, INC. | $17.21 | 2023 | Crysvita |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.92 | 2022 | |
| Kci USA, INC. | $16.22 | 2021 | |
| Medtronic, INC. | $13.14 | 2023 | Minimed 780g |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Blanchard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.